spacer
home > ebr > spring 2002 > the patenting of biotechnology in canada
PUBLICATIONS
European Biopharmaceutical Review

The Patenting of Biotechnology in Canada

Unlike in the US or Europe, there are no clear guidelines in Canada governing patenting requirements in the field of biotechnology, and case law is limited. In the absence of domestic policy or law, the Canadian Patent Office is greatly influenced by the practices of the US and European patent offices. This approach has been endorsed by the Canadian courts, who have frequently turned to other jurisdictions for guidance when domestic law is lacking. In recent decisions, such as the Federal Court Trial Division in Monsanto Canada Inc. versus Schmeiser (2001), 12 C.P.R. (4th) 204 (F.C.T.D.); the Federal Court of Appeal in The President and Fellows of Harvard College versus Canada (Commissioner of Patents) (2000), 7 C.P.R. (4th) 1 [hereinafter Harvard College, Supra]; and the Supreme Court of Canada in Free World Trust versus Electro Sante Inc. (2000), 9 C.P.R. (4th) 168, the Courts espoused the value of referring to US case law and practice to provide guidance in the development of Canadian patent law.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
By Anita Nador, Partner in the Biotechnology and Pharmaceutical Practice Group at Bereskin & Parr

Anita Nador is a Partner with Bereskin & Parr in their Biotechnology and Pharmaceutical Practice Group. She received a BA in Molecular Biophysics and Biochemistry from Yale University in 1986 and undertook research at Harvard Medical School and at a major Canadian pharmaceutical company before obtaining a Law degree from the University of Toronto in 1993.
Anita was called to the bar of Ontario in 1995 and is a registered Canadian patent and trademark agent. She is also registered to practice before the US Patent Office. Anita's practice is specialised in the area of intellectual property - particularly in biotechnology and pharmaceutical patent - plant breeders' rights, and trademark and licensing matters.

spacer
Anita Nador
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market explored ahead of CPhI MEA

Saudi Arabia’s pharmaceutical market expected to grow at a CAGR of 5.5% until 2023. Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth
More info >>

White Papers
 
Industry Events

World Vaccine Congress Europe

28-31 October 2019, Barcelona, Spain

The 20th annual World Vaccine Congress Europe is taking place 28-31 Oct in Barcelona. It’s the biggest and most established European vaccine event with over 250 speakers, 700+ senior vaccine attendees, hundreds of networking hours. It cover key topics across the complete vaccine value chain bringing together: • Government • big pharma • big biotech • SME Biotech • academia and the wider service provider community and their partners to discuss scientific, clinical and strategic advances and opportunities. The event has already confirmed over 200 speakers from Human Vaccine Project, OECD, CEPI, European Commission, FDA, WHO, OECD, NIH, GSK and many more… There is a Super Early Bird offer available – Find Out More www.terrapinn.com/WVCEU/EBR
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement